Overview
| Name | Beacon (Inductive Bio) · aliases: Beacon-2, Inductive Bio Beacon |
|---|---|
| Full name | A product name with no expanded form |
| Ambiguous names (not auto-linked) | Beacon |
| Family | Beacon is the ADMET model; Beacon-2 adds human dose estimation, and the challenge wins belong to Beacon, not Beacon-2
|
| Organization | Inductive Bio |
| Organization type | Platform company |
| Country | United States |
| Model class | Property prediction (ADMET / PK) |
| Domain | Small molecules |
| First release | † partly verified · product update Basis: Press coverage of the company with its Beacon platform (model release date not given; month approximate) source |
| Other milestones | |
| Latest update | † partly verified · successor Basis: Beacon-2 launch (secondary report) Beacon-2 adds human efficacious-dose prediction; a medicinal-chemistry agent, Indy, was introduced days earlier Note: The original press release was not opened; date from secondary reports source The most recent sourced event, not a claim that nothing changed since. |
| Status | Product only, no public artifact · Closed commercial product with successor Beacon-2 |
| Openness | Code: Closed Weights: Closed Closed; provided to partners through the company platform |
| Benchmarks reported | 0 counted (unconfirmed 1) |
| Wet-lab validation | None recorded |
| Unverified fields | † first_release, latest_update, release_milestones.first_public_evidence, training_data.c_own_wetlab_for_training, benchmarks_reported[0] |
| As of | 2026-11-17 |
What it does
Predicts ADMET and pharmacokinetic properties before a compound is made, fine-tuned for each partner's chemical space; Beacon-2 adds human dose estimates. It shares the ADMET route with ADMET-AI and MiniMol, but its training data come from a consortium pooling IP-protected data from several companies.
Benchmarks reported
Every row is one pairing from the survey's relation file; a score belongs to the benchmark page's ranking, where it is shown with metric, eval set, source type and date. 0 of 1 pairings are counted.
| Benchmark | Relation | Eval set / protocol | Source type | Note and evidence |
|---|---|---|---|---|
| 27 Polaris / ASAP / OpenADMET | Unconfirmed (not counted) | — | Unconfirmed source | Press release only; organiser anonymises entries; model identity unverified †disputed · evidence |
Other evaluations (outside the 44)
- OpenADMET blind challenges (Public benchmark not among the 44) Self-reported: The press release claims first place in antiviral, ExpansionRx and PXR challenges; only one is echoed by a third-party write-up and no official final board was read
- Beacon-2 dose estimation (Own task set) Self-reported: Dose prediction on ExpansionRx public compounds (secondary reports); sources give inconsistent figures
- Partner fine-tuning (user or partner report) Self-reported: Fine-tuned per partner on consortium data; scale not disclosed
Developers report: repeated first places in blind ADMET challenges, with consortium data and partner fine-tuning capturing subtle structural signals; Beacon-2 adds human dose estimates.
Independent evidence: No independent evidence found. The challenges are organiser-run, but only press releases and secondary reports were read; the boards are pseudonymous and no matching entry was verified
Training data
Group in Figure 7: Private or licensed data.
| Class | Value | Detail |
|---|---|---|
| a. Public databases | Yes | Public data used; libraries not named source |
| b. Private or licensed data | Yes | A pre-competitive consortium pooling anonymised partner data; compound and assay counts unpublished source |
| c. Own wet-lab data used for training | Not disclosed | No statement of own experimental data |
| d. Wet lab used only for validation | No | Blind challenges are external tests, not own wet lab |
Wet-lab validation
None. The developers report no wet-lab validation.
Background
- Organization: Inductive Bio is based in New York and does not develop its own drugs; it commercialises a pre-competitive consortium where companies contribute anonymised data under IP protection and clients pay software and collaboration fees. It left stealth in 2023-12.
- Funding: About $4.3M seed disclosed at launch (a16z Bio + Health and Lux Capital); a $25M Series A led by Obvious Ventures announced in 2025-05.
- Products and partnerships: Products are the Compass platform, the Beacon models and the chemistry assistant Indy; Denali Therapeutics is an early partner; with Ginkgo Datapoints and Tangible Scientific it forms an assay, modelling and compound-management workflow.
- Related models: ADMET-AI, MiniMol
Reading notes
- First places suggest strong results on those datasets, but the evidence is company press releases and the boards are pseudonymous.
- Consortium data size is undisclosed, so it is unclear whether the edge comes from the model or the data.
- "Consecutive wins" is a point-in-time claim and needs a date when cited.
- The two second-hand dose-estimation figures for Beacon-2 must not be mixed.
Caveats
- The Polaris pairing is not established: identity cannot be verified and two challenges were outside the Polaris hub.
- Beacon-2's launch date and description come from secondary reports.
- The first-release month is approximate; no public release date exists for the model itself.
Sources
- Company press release (PXR challenge) (press)
- Beacon-2 coverage (second-hand) second-hand
- Series A coverage (press)
- Company interview coverage (press)
- OpenADMET challenge lessons write-up (third-party paper)
- Stealth exit coverage (press)
Corrections
1 correction
| Field | Was | Now | Basis | Found |
|---|---|---|---|---|
| benchmarks_reported | First in three Polaris blind challenges (self-reported) | Unconfirmed and not counted: the board is anonymous, and two of the events are not on the Polaris platform | source | 2026-11-16 |
Part of the AI for Bio benchmarks survey · all 112 models · open in the explorer. Record as of 2026-11-17.